ANTI-TGF-BETA ANTIBODY FOR THE TREATMENT OF FANCONI ANEMIA

The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11. La présente invention concerne des...

Full description

Saved in:
Bibliographic Details
Main Authors ZHANG, Haojian, PARMAR, Kalindi, D'ANDREA, Alan
Format Patent
LanguageEnglish
French
Published 01.09.2016
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11. La présente invention concerne des procédés de traitement, de prévention ou de retardement de l'apparition d'une défaillance de la moelle osseuse chez des patients souffrant d'anémie de Fanconi, comprenant l'administration au patient d'une composition qui comprend un anticorps anti-TGF-bêta de neutralisation, par exemple fresolimumab ou 1D11.
Bibliography:Application Number: WO2016US19626